• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

珍珠中的天然生物活性肽可用作 COVID-19 中 SARS-CoV-2 和 ACE2 相互作用的潜在抑制剂。

A Natural Bioactive Peptide from Pearls Can Be Used as a Potential Inhibitor of the Interaction between SARS-CoV-2 and ACE2 against COVID-19.

机构信息

Department of Biotechnology and Biomedicine, Yangtze Delta Region Institute of Tsinghua University, Jiaxing 314006, China.

Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, 705 Yatai Road, Jiaxing 314006, China.

出版信息

Int J Mol Sci. 2024 Jul 19;25(14):7902. doi: 10.3390/ijms25147902.

DOI:10.3390/ijms25147902
PMID:39063143
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11277083/
Abstract

The frequent occurrence of viral infections poses a serious threat to human life. Identifying effective antiviral components is urgent. In China, pearls have been important traditional medicinal ingredients since ancient times, exhibiting various therapeutic properties, including detoxification properties. In this study, a peptide, KKCH, which acts against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was derived from pearls. Molecular docking showed that it bound to the same pocket of the SARS-CoV-2 S protein and cell surface target angiotensin-converting enzyme II (ACE2). The function of KKCH was analyzed through surface plasmon resonance (SPR), Enzyme-Linked Immunosorbent Assays, immunofluorescence, and simulation methods using the SARS-CoV-2 pseudovirus and live virus. The results showed that KKCH had a good affinity for ACE2 (KD = 6.24 × 10 M) and could inhibit the binding of the S1 protein to ACE2 via competitive binding. As a natural peptide, KKCH inhibited the binding of the SARS-CoV-2 S1 protein to the surface of human BEAS-2B and HEK293T cells. Moreover, viral experiments confirmed the antiviral activity of KKCH against both the SARS-CoV-2 spike pseudovirus and SARS-CoV-2 live virus, with half-maximal inhibitory concentration (IC) values of 398.1 μM and 462.4 μM, respectively. This study provides new insights and potential avenues for the prevention and treatment of SARS-CoV-2 infections.

摘要

病毒感染的频繁发生对人类生命构成了严重威胁。寻找有效的抗病毒成分迫在眉睫。在中国,珍珠自古以来就是重要的传统药用成分,具有多种治疗特性,包括解毒特性。在这项研究中,一种从珍珠中提取的针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的肽 KKCH。分子对接表明,它与 SARS-CoV-2 S 蛋白和细胞表面靶标血管紧张素转换酶 II (ACE2) 的相同口袋结合。通过表面等离子体共振 (SPR)、酶联免疫吸附试验、免疫荧光和使用 SARS-CoV-2 假病毒和活病毒的模拟方法分析了 KKCH 的功能。结果表明,KKCH 对 ACE2 具有良好的亲和力 (KD = 6.24 × 10 M),并可以通过竞争性结合抑制 S1 蛋白与 ACE2 的结合。作为一种天然肽,KKCH 抑制了 SARS-CoV-2 S1 蛋白与人 BEAS-2B 和 HEK293T 细胞表面的结合。此外,病毒实验证实了 KKCH 对 SARS-CoV-2 刺突假病毒和 SARS-CoV-2 活病毒的抗病毒活性,半数最大抑制浓度 (IC) 值分别为 398.1 μM 和 462.4 μM。这项研究为 SARS-CoV-2 感染的预防和治疗提供了新的见解和潜在途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/98fed8506c64/ijms-25-07902-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/232e1027f23b/ijms-25-07902-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/942d8751ca8b/ijms-25-07902-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/722cd5390ef1/ijms-25-07902-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/98fed8506c64/ijms-25-07902-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/232e1027f23b/ijms-25-07902-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/942d8751ca8b/ijms-25-07902-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/722cd5390ef1/ijms-25-07902-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba0/11277083/98fed8506c64/ijms-25-07902-g004.jpg

相似文献

1
A Natural Bioactive Peptide from Pearls Can Be Used as a Potential Inhibitor of the Interaction between SARS-CoV-2 and ACE2 against COVID-19.珍珠中的天然生物活性肽可用作 COVID-19 中 SARS-CoV-2 和 ACE2 相互作用的潜在抑制剂。
Int J Mol Sci. 2024 Jul 19;25(14):7902. doi: 10.3390/ijms25147902.
2
An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.血管紧张素转换酶 2 衍生的七肽 GK-7 可阻断 SARS-CoV-2 刺突蛋白。
Peptides. 2021 Nov;145:170638. doi: 10.1016/j.peptides.2021.170638. Epub 2021 Aug 19.
3
Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.揭示 SARS-CoV-1/CoV-2 刺突蛋白通过 ACE2 设计肽的抑制机制。
J Chem Inf Model. 2021 Mar 22;61(3):1226-1243. doi: 10.1021/acs.jcim.0c01320. Epub 2021 Feb 23.
4
Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.SARS-CoV-2 及其新兴变异株的进入抑制剂的发现和评估。
J Virol. 2021 Nov 23;95(24):e0143721. doi: 10.1128/JVI.01437-21. Epub 2021 Sep 22.
5
Interactions between ACE2 and SARS-CoV-2 S Protein: Peptide Inhibitors for Potential Drug Developments Against COVID-19.ACE2 与 SARS-CoV-2 S 蛋白相互作用:针对 COVID-19 的潜在药物开发的肽抑制剂。
Curr Protein Pept Sci. 2021;22(10):729-744. doi: 10.2174/1389203722666210916141924.
6
Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.理性设计的 ACE2 衍生肽抑制 SARS-CoV-2。
Bioconjug Chem. 2021 Jan 20;32(1):215-223. doi: 10.1021/acs.bioconjchem.0c00664. Epub 2020 Dec 24.
7
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.多学科方法鉴定与人 ACE2 或 SARS-CoV-2 刺突蛋白结合的化合物,作为阻断 SARS-CoV-2-ACE2 受体相互作用的候选药物。
mBio. 2021 Mar 30;12(2):e03681-20. doi: 10.1128/mBio.03681-20.
8
Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.麻黄中的活性成分破坏 ACE2 与 SARS-CoV-2 RBD 的相互作用:有效的 COVID-19 治疗药物。
J Ethnopharmacol. 2021 Oct 5;278:114303. doi: 10.1016/j.jep.2021.114303. Epub 2021 Jun 5.
9
Withanone from Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model.Withanone 抑制 SARS-CoV-2 RBD 与宿主 ACE2 的相互作用,挽救人源化斑马鱼模型中 Spike 蛋白诱导的病理损伤。
Drug Des Devel Ther. 2021 Mar 11;15:1111-1133. doi: 10.2147/DDDT.S292805. eCollection 2021.
10
Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.山奈酚对 SARS-CoV-2 刺突假病毒的体外潜在抗病毒活性。
Drug Dev Res. 2021 Dec;82(8):1124-1130. doi: 10.1002/ddr.21815. Epub 2021 Apr 13.

引用本文的文献

1
Pseudotyped Viruses: A Useful Platform for Pre-Clinical Studies Conducted in a BSL-2 Laboratory Setting.假型病毒:在生物安全二级(BSL-2)实验室环境中进行临床前研究的有用平台。
Biomolecules. 2025 Jan 15;15(1):135. doi: 10.3390/biom15010135.
2
From Sea to Lab: Angiotensin I-Converting Enzyme Inhibition by Marine Peptides-Mechanisms and Applications.从海洋到实验室:海洋肽对血管紧张素转化酶的抑制作用——机制与应用。
Mar Drugs. 2024 Sep 30;22(10):449. doi: 10.3390/md22100449.

本文引用的文献

1
The first bioactive (angiotensin-converting enzyme-inhibitory) peptide isolated from pearl matrix protein.从珍珠基质蛋白中分离出的首个具有生物活性(血管紧张素转换酶抑制)的肽。
Heliyon. 2024 Mar 18;10(7):e28060. doi: 10.1016/j.heliyon.2024.e28060. eCollection 2024 Apr 15.
2
Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection.肾类器官揭示 ACE2 依赖性 SARS-CoV-2 感染过程中病毒进入途径的冗余性。
J Virol. 2024 Mar 19;98(3):e0180223. doi: 10.1128/jvi.01802-23. Epub 2024 Feb 9.
3
Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116).
小分子抗新冠病毒药物及对中国本土的民得维(VV116)的关注
Front Med. 2023 Dec;17(6):1068-1079. doi: 10.1007/s11684-023-1037-3. Epub 2024 Jan 2.
4
P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation.P21 激活激酶 1(PAK1)介导的细胞骨架重排促进了 SARS-CoV-2 的进入和 ACE2 的自噬降解。
Signal Transduct Target Ther. 2023 Oct 9;8(1):385. doi: 10.1038/s41392-023-01631-0.
5
Molnupiravir and Nirmatelvir/Ritonavir in the Treatment of Patients With Systemic Autoimmune Rheumatic Disease With SARS-CoV-2.莫努匹拉韦和奈玛特韦/利托那韦治疗合并新型冠状病毒肺炎的系统性自身免疫性风湿病患者
J Rheumatol. 2023 Aug;50(8):974-975. doi: 10.3899/jrheum.2023-0205. Epub 2023 May 1.
6
Sensing Mechanisms of Rough Plasmonic Surfaces for Protein Binding of Surface Plasmon Resonance Detection.用于表面等离子体共振检测的粗糙等离子体表面的蛋白质结合传感机制。
Sensors (Basel). 2023 Mar 23;23(7):3377. doi: 10.3390/s23073377.
7
Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023.2022 - 2023年秋冬因新冠病毒病住院患者与季节性流感患者的死亡风险
JAMA. 2023 May 16;329(19):1697-1699. doi: 10.1001/jama.2023.5348.
8
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines.2019冠状病毒病最新情况:严重急性呼吸综合征冠状病毒2变种、抗病毒药物及疫苗
Heliyon. 2023 Mar;9(3):e13952. doi: 10.1016/j.heliyon.2023.e13952. Epub 2023 Feb 23.
9
An overview on the treatments and prevention against COVID-19.关于 COVID-19 的治疗和预防概述。
Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9.
10
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.全球新兴的 SARS-CoV-2 奥密克戎变异株:影响、挑战与策略。
J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19.